Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock.
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium